Most Read News

EBITDA increased 20.3% to ₹191.7 crore in the March 2025 quarter from ₹159.4 crore a year ago.

Headline CPI drops. There’s more to the story as core CPI remains elevated. Will RBI continue its accommodative stance as widely expected?

This latest order enlarges TCS’s continued engagement with BSNL to modernise the state-run telecom operator’s mobile infrastructure.

Bharat Elec is the only stock to hits 52-week high in Nifty

Most of the IPO proceeds will be used for deleveraging, allowing for better margins and financial flexibility.

Revenue from operations increased by 38.8% YoY to ₹163 crore against ₹117.4 crore reported in the corresponding period last year.

As per the company’s filing with the bourses, Biocon Biologics has developed and manufactured this injection while Yoshindo Inc.

The issue may be done through public offers or private placements. This subject to market conditions, and regulatory approvals, stated the public lender.

The contract is for executing KAVACH, an indigenous train collision avoidance system, in 778 route kilometers in the Bengaluru and Mysuru divisions.

The Board has proposed a final dividend of ₹6 per share and has also approved a new dividend policy of giving back up to 75% of free cash flow in the future.